|
AU2012202877A1
|
|
1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
|
|
AU2008200524A1
|
|
A cell therapy method for the treatment of tumors
|
|
EP2061904A2
|
|
Biomarkers for assessing response to c-met treatment
|
|
AU2007201369A1
|
|
The human voltage gated sodium channel BETA-1A subunit and methods of use
|
|
AU2006235898A1
|
|
3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
|
|
US2006258859A1
|
|
Phenylalkynes
|
|
AU2006202900A1
|
|
Substituted imidazoles useful in the treatment of inflammatory diseases
|
|
ZA200603486B
|
|
Arylindenopyridines and arylindenopyridines and their use as adenosine A2a receptor antagonist
|
|
AU2006200853A1
|
|
Combinational therapy involving a small molecule inhibitor of the MDM2: P53 interaction
|
|
AU2005209613A1
|
|
Method of isolating CD8+ cells, and related hybridoma cells, antibodies and polypeptides
|
|
AU2005203607A1
|
|
Antibacterial heterobicyclic substituted phenyl oxazolidinones
|
|
US2006040866A1
|
|
Peptides and compounds that bind to a receptor
|
|
US2005239812A1
|
|
Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
|
|
AU2005265248A1
|
|
Methods for measuring chloride channel conductivity
|
|
AU2005202100A1
|
|
Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
|
|
WO2005049043A1
|
|
Combination therapy comprising metformin and anticonvulsant agents
|
|
US7427683B2
|
|
c-fms kinase inhibitors
|
|
ZA200407377B
|
|
Topiramate salts and compositions comprising and methods of making and using the same.
|
|
SG131110A1
|
|
Peptides and compounds that bind to thrombopoietin receptors
|
|
US7205384B2
|
|
Process for preparing peptidyl heterocyclic ketone derivatives
|
